ONCO (Onconetix) Total Operating Expense: $7.37 Mil (TTM As of Mar. 2026)


ONCO Onconetix Inc ONCO
19 GF Score
Price $0.94
! 4 Warning Signs
View Full Analysis

What is Onconetix Total Operating Expense?

Onconetix ONCO -4.62% 19 Total Operating Expense is $7.37 Mil as of Mar. 2026. GuruFocus rates ONCO with a GF Score™ of 19/100. The stock has 4 warning signs investors should review.

Onconetix's Total Operating Expense for the three months ended in Mar. 2026 was $2.09 Mil. Onconetix's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $7.37 Mil.

Onconetix Total Operating Expense Related Terms

Onconetix Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Onconetix's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Onconetix Total Operating Expense Chart

Onconetix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 3.42 13.48 16.72 11.39 6.98

Onconetix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.70 1.41 2.34 1.53 2.09
ONCO
19GF Score
Onconetix Inc ONCO
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Onconetix Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $7.37 Mil mean?
Onconetix (ONCO) has a Total Operating Expense of $7.37 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Onconetix and its competitors.
Is Onconetix's Total Operating Expense too high?
Onconetix's current Total Operating Expense is $7.37 Mil. Overall, Onconetix has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Onconetix's Total Operating Expense compare to CMND and REVB?
Onconetix's Total Operating Expense of $7.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Onconetix and its competitors. Onconetix's current Total Operating Expense is $7.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onconetix stock overvalued right now?
Onconetix (ONCO) has a current Total Operating Expense of $7.37 Mil. The current Total Operating Expense is $7.37 Mil. Onconetix's overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Onconetix (ONCO), the current Total Operating Expense is $7.37 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Onconetix Business Description

Address 201 E. Fifth Street, Suite 1900, Cincinnati, OH, USA, 45202
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
19GF Score

Get the complete analysis for ONCO

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.94
Price